Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1971 1
1974 2
1977 3
1978 2
1979 2
1980 3
1981 4
1982 3
1983 5
1984 6
1985 8
1986 7
1987 12
1988 16
1989 15
1990 17
1991 14
1992 22
1993 23
1994 17
1995 12
1996 14
1997 14
1998 6
1999 13
2000 8
2001 15
2002 15
2003 18
2004 7
2005 12
2006 20
2007 21
2008 19
2009 17
2010 25
2011 18
2012 20
2013 29
2014 26
2015 28
2016 22
2017 17
2018 12
2019 14
2020 18
2021 15
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

609 results
Results by year
Filters applied: . Clear all
Page 1
Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MA. Bar-Or A, et al. Among authors: steinman l. Trends Mol Med. 2020 Mar;26(3):296-310. doi: 10.1016/j.molmed.2019.11.003. Epub 2019 Dec 17. Trends Mol Med. 2020. PMID: 31862243 Free PMC article. Review.
Epstein-Barr virus and multiple sclerosis.
Robinson WH, Steinman L. Robinson WH, et al. Among authors: steinman l. Science. 2022 Jan 21;375(6578):264-265. doi: 10.1126/science.abm7930. Epub 2022 Jan 13. Science. 2022. PMID: 35025606
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.
Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj GS, Bartley CM, Schubert RD, Hawes IA, Vazquez SE, Iyer M, Zuchero JB, Teegen B, Dunn JE, Lock CB, Kipp LB, Cotham VC, Ueberheide BM, Aftab BT, Anderson MS, DeRisi JL, Wilson MR, Bashford-Rogers RJM, Platten M, Garcia KC, Steinman L, Robinson WH. Lanz TV, et al. Among authors: steinman l. Nature. 2022 Mar;603(7900):321-327. doi: 10.1038/s41586-022-04432-7. Epub 2022 Jan 24. Nature. 2022. PMID: 35073561
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators. Comi G, et al. Among authors: steinman l. Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492651 Clinical Trial.
Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist.
Glassman CR, Su L, Majri-Morrison SS, Winkelmann H, Mo F, Li P, Pérez-Cruz M, Ho PP, Koliesnik I, Nagy N, Hnizdilova T, Picton LK, Kovar M, Bollyky P, Steinman L, Meyer E, Piehler J, Leonard WJ, Garcia KC. Glassman CR, et al. Among authors: steinman l. Elife. 2021 May 18;10:e65777. doi: 10.7554/eLife.65777. Elife. 2021. PMID: 34003116 Free PMC article.
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators. Cohen JA, et al. Among authors: steinman l. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492652 Clinical Trial.
Autoimmune disease.
Steinman L. Steinman L. Sci Am. 1993 Sep;269(3):106-14. doi: 10.1038/scientificamerican0993-106. Sci Am. 1993. PMID: 8211084 Review. No abstract available.
609 results